English

Axsome Therapeutics, Inc.

EDGAR

AXSM Quarterly report (10-Q) · filed 2026-08-10

Annual consolidated revenue for 2025: about USD 638.5M, using the latest reported figures. The previous period, 2024, was about USD 385.7M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

218 million USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 218375000 USD Source

Operating margin

-22.73%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -49646000 USD Source
Revenue: 218375000 USD Source

Operating cash flow

-33 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -53652000 USD Source
Operating Cash Flow: -20700000 USD Source

Free cash flow

-33.4 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -53652000 USD Source
Operating Cash Flow: -20700000 USD Source
Capital Expenditure: 571000 USD Source
Capital Expenditure: 121000 USD Source

Cash and cash equivalents: 320 million USD 2026-06-30 Source
Exact value

319850000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 52.3 million shares 2026-06-30 Source
Exact value

52299889 shares

Reported share-count change

4.99% · 2.48 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

49815301 shares · 2025-06-30· Source
52299889 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

777 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 170992000 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 638496000 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 442497000 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 191203000 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 218375000 USD · 2026-04-01 – 2026-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-10.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 4 of 11 periods available· newest 2025-12-31
Operating income: 8 of 11 periods available· newest 2025-12-31
Net income: 8 of 11 periods available· newest 2025-12-31
Operating cash flow: 8 of 11 periods available· newest 2025-12-31
Capital expenditure: 8 of 11 periods available· newest 2025-12-31
Total assets: 4 of 11 periods available· newest 2025-12-31
Total liabilities: 4 of 11 periods available· newest 2025-12-31
Current assets: 4 of 11 periods available· newest 2025-12-31
Current liabilities: 4 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 4 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 4 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+65.5%

Prior period

USD 385.69 million

2024-01-01 – 2024-12-31
Current period

USD 638.5 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

638496000 − 385693000 = 252803000 USD

385693000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
638496000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Axsome Therapeutics, Inc. · 2025-12-31 Axsome Therapeutics, Inc. (edgar:1579428) Year-over-year change in Revenue: 252803000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T02:31:15Z Snapshot: ed93b97d7751e86c88e7f066397fde99ed23043f4255bb6f82705bc602c0f118 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1579428?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 638496000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000119312526064267/axsm-20251231.htm#3674952 Filing: 000119312526064267 Input fundies:Revenue: 385693000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000119312526064267/axsm-20251231.htm#3676622 Filing: 000119312526064267
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 104.04 million

Prior period

−USD 287.22 million

2024-01-01 – 2024-12-31
Current period

−USD 183.17 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-183174000 − -287216000 = 104042000 USD

-287216000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-183174000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Axsome Therapeutics, Inc. · 2025-12-31 Axsome Therapeutics, Inc. (edgar:1579428) Year-over-year change in Net income: 104042000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T02:31:15Z Snapshot: ed93b97d7751e86c88e7f066397fde99ed23043f4255bb6f82705bc602c0f118 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1579428?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -183174000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000119312526064267/axsm-20251231.htm#3778660 Filing: 000119312526064267 Input fundies:NetIncome: -287216000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000119312526064267/axsm-20251231.htm#3780515 Filing: 000119312526064267
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 35.01 million

Prior period

−USD 128.41 million

2024-01-01 – 2024-12-31
Current period

−USD 93.41 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-93405000 − -128410000 = 35005000 USD

-128410000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-93405000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Axsome Therapeutics, Inc. · 2025-12-31 Axsome Therapeutics, Inc. (edgar:1579428) Year-over-year change in Operating cash flow: 35005000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T02:31:15Z Snapshot: ed93b97d7751e86c88e7f066397fde99ed23043f4255bb6f82705bc602c0f118 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1579428?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -93405000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000119312526064267/axsm-20251231.htm#2133272 Filing: 000119312526064267 Input fundies:OperatingCashFlow: -128410000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000119312526064267/axsm-20251231.htm#2135152 Filing: 000119312526064267
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+77.8%

Prior period

USD 270,000

2024-01-01 – 2024-12-31
Current period

USD 480,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

480000 − 270000 = 210000 USD

270000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
480000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Axsome Therapeutics, Inc. · 2025-12-31 Axsome Therapeutics, Inc. (edgar:1579428) Year-over-year change in Capital expenditure: 210000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T02:31:15Z Snapshot: ed93b97d7751e86c88e7f066397fde99ed23043f4255bb6f82705bc602c0f118 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1579428?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 480000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000119312526064267/axsm-20251231.htm#2142829 Filing: 000119312526064267 Input fundies:CapitalExpenditure: 270000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000119312526064267/axsm-20251231.htm#2144593 Filing: 000119312526064267
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 638.5 million 100% of revenue
Operating costs Derived USD 805.26 million 126% of revenue
Operating income −USD 166.76 million −26% of revenue
Tax, interest and other Derived USD 16.41 million 2.6% of revenue
Net income −USD 183.17 million −29% of revenue

Cash

Operating cash flow −USD 93.41 million −15% of revenue
Capital expenditure USD 480,000 0.1% of revenue
Free cash flow Derived −USD 93.89 million −15% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2022 Operating loss: operating costs were 459% of revenue.
2023 Operating loss: operating costs were 186% of revenue.
2024 Operating loss: operating costs were 173% of revenue.
2025 Operating loss: operating costs were 126% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2022 2022-01-01 – 2022-12-31	50037000	229836000 Derived	-179799000	7335000 Derived	-187134000	-117213000 Derived	Source 2022-01-01 – 2022-12-31: 50037000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -179799000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -187134000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -116511000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 702000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	270600000	502425000 Derived	-231825000	7413000 Derived	-239238000	-145662000 Derived	Source 2023-01-01 – 2023-12-31: 270600000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -231825000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -239238000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -145080000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 582000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	385693000	666255000 Derived	-280562000	6654000 Derived	-287216000	-128680000 Derived	Source 2024-01-01 – 2024-12-31: 385693000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -280562000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -287216000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -128410000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 270000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	638496000	805258000 Derived	-166762000	16412000 Derived	-183174000	-93885000 Derived	Source 2025-01-01 – 2025-12-31: 638496000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -166762000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -183174000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -93405000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 480000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 638.5M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20222022-12-31	Revenue	50037000	Revenue: 50037000 Open source
20232023-12-31	Revenue	270600000	Revenue: 270600000 Open source
20242024-12-31	Revenue	385693000	Revenue: 385693000 Open source
20252025-12-31	Revenue	638496000	Revenue: 638496000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

65.5% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20222022-12-31	Year over year	No prior comparable period	Revenue: 50037000 Open source
20232023-12-31	Year over year	440.8%	Revenue: 270600000 Open source Revenue: 50037000 Open source
20242024-12-31	Year over year	42.5%	Revenue: 385693000 Open source Revenue: 270600000 Open source
20252025-12-31	Year over year	65.5%	Revenue: 638496000 Open source Revenue: 385693000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -26.1% 2025

Net margin -28.7% 2025

Free cash flow margin -14.7% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20222022-12-31	Operating margin	-359.3%	Operating Income: -179799000 Open source Revenue: 50037000 Open source
20232023-12-31	Operating margin	-85.7%	Operating Income: -231825000 Open source Revenue: 270600000 Open source
20242024-12-31	Operating margin	-72.7%	Operating Income: -280562000 Open source Revenue: 385693000 Open source
20252025-12-31	Operating margin	-26.1%	Operating Income: -166762000 Open source Revenue: 638496000 Open source
20222022-12-31	Net margin	-374%	Net Income: -187134000 Open source Revenue: 50037000 Open source
20232023-12-31	Net margin	-88.4%	Net Income: -239238000 Open source Revenue: 270600000 Open source
20242024-12-31	Net margin	-74.5%	Net Income: -287216000 Open source Revenue: 385693000 Open source
20252025-12-31	Net margin	-28.7%	Net Income: -183174000 Open source Revenue: 638496000 Open source
20222022-12-31	Free cash flow margin	-234.3%	Revenue: 50037000 Open source Operating Cash Flow: -116511000 Open source Capital Expenditure: 702000 Open source
20232023-12-31	Free cash flow margin	-53.8%	Revenue: 270600000 Open source Operating Cash Flow: -145080000 Open source Capital Expenditure: 582000 Open source
20242024-12-31	Free cash flow margin	-33.4%	Revenue: 385693000 Open source Operating Cash Flow: -128410000 Open source Capital Expenditure: 270000 Open source
20252025-12-31	Free cash flow margin	-14.7%	Revenue: 638496000 Open source Operating Cash Flow: -93405000 Open source Capital Expenditure: 480000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -93.4M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20222022-12-31	Operating cash flow	-116511000	Operating Cash Flow: -116511000 Open source
20232023-12-31	Operating cash flow	-145080000	Operating Cash Flow: -145080000 Open source
20242024-12-31	Operating cash flow	-128410000	Operating Cash Flow: -128410000 Open source
20252025-12-31	Operating cash flow	-93405000	Operating Cash Flow: -93405000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -93.9M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20222022-12-31	Free cash flow	-117213000	Operating Cash Flow: -116511000 Open source Capital Expenditure: 702000 Open source
20232023-12-31	Free cash flow	-145662000	Operating Cash Flow: -145080000 Open source Capital Expenditure: 582000 Open source
20242024-12-31	Free cash flow	-128680000	Operating Cash Flow: -128410000 Open source Capital Expenditure: 270000 Open source
20252025-12-31	Free cash flow	-93885000	Operating Cash Flow: -93405000 Open source Capital Expenditure: 480000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

87.2% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20222022-12-31	Liabilities / assets	66.9%	Total Liabilities: 221920000 Open source Total Assets: 331476000 Open source
20232023-12-31	Liabilities / assets	67.5%	Total Liabilities: 397259000 Open source Total Assets: 588236000 Open source
20242024-12-31	Liabilities / assets	90%	Total Liabilities: 511483000 Open source Total Assets: 568498000 Open source
20252025-12-31	Liabilities / assets	87.2%	Total Liabilities: 601510000 Open source Total Assets: 689805000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

1.55× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20222022-12-31	Current assets / current liabilities	2.54×	Current Assets: 245642000 Open source Current Liabilities: 96561000 Open source
20232023-12-31	Current assets / current liabilities	3.63×	Current Assets: 504263000 Open source Current Liabilities: 138854000 Open source
20242024-12-31	Current assets / current liabilities	2.11×	Current Assets: 485064000 Open source Current Liabilities: 230104000 Open source
20252025-12-31	Current assets / current liabilities	1.55×	Current Assets: 588986000 Open source Current Liabilities: 378836000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2018 2018-01-01 – 2018-12-31	−USD 30.97 million Exact value Exact value: -30965464 USD 2018-01-01 – 2018-12-31: -30965464 USD Inspect Net Income Open source Share or cite Citation for Net Income · Axsome Therapeutics, Inc. · 2018-12-31 Axsome Therapeutics, Inc. (edgar:1579428) Net Income: -30965464 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T02:31:15Z Snapshot: ed93b97d7751e86c88e7f066397fde99ed23043f4255bb6f82705bc602c0f118 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1579428/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -30965464 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000156459021009924/axsm-10k_20201231.htm#2447871 Filing: 000156459021009924 The citation records this snapshot. The page link may show a newer release later.	−USD 30.05 million Exact value Exact value: -30053701 USD 2018-01-01 – 2018-12-31: -30053701 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Axsome Therapeutics, Inc. · 2018-12-31 Axsome Therapeutics, Inc. (edgar:1579428) Operating Cash Flow: -30053701 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T02:31:15Z Snapshot: ed93b97d7751e86c88e7f066397fde99ed23043f4255bb6f82705bc602c0f118 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1579428/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -30053701 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000156459021009924/axsm-10k_20201231.htm#2261518 Filing: 000156459021009924 The citation records this snapshot. The page link may show a newer release later.	USD 32,696 Exact value Exact value: 32696 USD 2018-01-01 – 2018-12-31: 32696 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Axsome Therapeutics, Inc. · 2018-12-31 Axsome Therapeutics, Inc. (edgar:1579428) Capital Expenditure: 32696 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T02:31:15Z Snapshot: ed93b97d7751e86c88e7f066397fde99ed23043f4255bb6f82705bc602c0f118 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1579428/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 32696 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000156459021009924/axsm-10k_20201231.htm#2273063 Filing: 000156459021009924 The citation records this snapshot. The page link may show a newer release later.	−USD 30.09 million Calculation and evidence -30053701 − 32696 USD Exact free cash flow: -30086397 USD 2018-01-01 – 2018-12-31: -30053701 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 32696 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Axsome Therapeutics, Inc. · 2018-12-31 Axsome Therapeutics, Inc. (edgar:1579428) Free cash flow: -30086397 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T02:31:15Z Snapshot: ed93b97d7751e86c88e7f066397fde99ed23043f4255bb6f82705bc602c0f118 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1579428?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -30053701 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000156459021009924/axsm-10k_20201231.htm#2261518 Filing: 000156459021009924 Input fundies:CapitalExpenditure: 32696 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000156459021009924/axsm-10k_20201231.htm#2273063 Filing: 000156459021009924 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 68.35 million Exact value Exact value: -68345186 USD 2019-01-01 – 2019-12-31: -68345186 USD Inspect Net Income Open source Share or cite Citation for Net Income · Axsome Therapeutics, Inc. · 2019-12-31 Axsome Therapeutics, Inc. (edgar:1579428) Net Income: -68345186 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T02:31:15Z Snapshot: ed93b97d7751e86c88e7f066397fde99ed23043f4255bb6f82705bc602c0f118 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1579428/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -68345186 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000095017022002568/axsm-20211231.htm#2158950 Filing: 000095017022002568 The citation records this snapshot. The page link may show a newer release later.	−USD 46.38 million Exact value Exact value: -46375059 USD 2019-01-01 – 2019-12-31: -46375059 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Axsome Therapeutics, Inc. · 2019-12-31 Axsome Therapeutics, Inc. (edgar:1579428) Operating Cash Flow: -46375059 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T02:31:15Z Snapshot: ed93b97d7751e86c88e7f066397fde99ed23043f4255bb6f82705bc602c0f118 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1579428/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -46375059 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000095017022002568/axsm-20211231.htm#1966436 Filing: 000095017022002568 The citation records this snapshot. The page link may show a newer release later.	USD 16,121 Exact value Exact value: 16121 USD 2019-01-01 – 2019-12-31: 16121 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Axsome Therapeutics, Inc. · 2019-12-31 Axsome Therapeutics, Inc. (edgar:1579428) Capital Expenditure: 16121 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T02:31:15Z Snapshot: ed93b97d7751e86c88e7f066397fde99ed23043f4255bb6f82705bc602c0f118 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1579428/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 16121 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000095017022002568/axsm-20211231.htm#1977044 Filing: 000095017022002568 The citation records this snapshot. The page link may show a newer release later.	−USD 46.39 million Calculation and evidence -46375059 − 16121 USD Exact free cash flow: -46391180 USD 2019-01-01 – 2019-12-31: -46375059 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 16121 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Axsome Therapeutics, Inc. · 2019-12-31 Axsome Therapeutics, Inc. (edgar:1579428) Free cash flow: -46391180 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T02:31:15Z Snapshot: ed93b97d7751e86c88e7f066397fde99ed23043f4255bb6f82705bc602c0f118 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1579428?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -46375059 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000095017022002568/axsm-20211231.htm#1966436 Filing: 000095017022002568 Input fundies:CapitalExpenditure: 16121 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000095017022002568/axsm-20211231.htm#1977044 Filing: 000095017022002568 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 102.9 million Exact value Exact value: -102900600 USD 2020-01-01 – 2020-12-31: -102900600 USD Inspect Net Income Open source Share or cite Citation for Net Income · Axsome Therapeutics, Inc. · 2020-12-31 Axsome Therapeutics, Inc. (edgar:1579428) Net Income: -102900600 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T02:31:15Z Snapshot: ed93b97d7751e86c88e7f066397fde99ed23043f4255bb6f82705bc602c0f118 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1579428/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -102900600 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000095017023004728/axsm-20221231.htm#3024320 Filing: 000095017023004728 The citation records this snapshot. The page link may show a newer release later.	−USD 78.46 million Exact value Exact value: -78456569 USD 2020-01-01 – 2020-12-31: -78456569 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Axsome Therapeutics, Inc. · 2020-12-31 Axsome Therapeutics, Inc. (edgar:1579428) Operating Cash Flow: -78456569 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T02:31:15Z Snapshot: ed93b97d7751e86c88e7f066397fde99ed23043f4255bb6f82705bc602c0f118 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1579428/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -78456569 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000095017023004728/axsm-20221231.htm#2233725 Filing: 000095017023004728 The citation records this snapshot. The page link may show a newer release later.	USD 45,891 Exact value Exact value: 45891 USD 2020-01-01 – 2020-12-31: 45891 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Axsome Therapeutics, Inc. · 2020-12-31 Axsome Therapeutics, Inc. (edgar:1579428) Capital Expenditure: 45891 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T02:31:15Z Snapshot: ed93b97d7751e86c88e7f066397fde99ed23043f4255bb6f82705bc602c0f118 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1579428/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 45891 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000095017023004728/axsm-20221231.htm#2245058 Filing: 000095017023004728 The citation records this snapshot. The page link may show a newer release later.	−USD 78.5 million Calculation and evidence -78456569 − 45891 USD Exact free cash flow: -78502460 USD 2020-01-01 – 2020-12-31: -78456569 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 45891 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Axsome Therapeutics, Inc. · 2020-12-31 Axsome Therapeutics, Inc. (edgar:1579428) Free cash flow: -78502460 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T02:31:15Z Snapshot: ed93b97d7751e86c88e7f066397fde99ed23043f4255bb6f82705bc602c0f118 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1579428?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -78456569 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000095017023004728/axsm-20221231.htm#2233725 Filing: 000095017023004728 Input fundies:CapitalExpenditure: 45891 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000095017023004728/axsm-20221231.htm#2245058 Filing: 000095017023004728 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 130.4 million Exact value Exact value: -130403000 USD 2021-01-01 – 2021-12-31: -130403000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Axsome Therapeutics, Inc. · 2021-12-31 Axsome Therapeutics, Inc. (edgar:1579428) Net Income: -130403000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T02:31:15Z Snapshot: ed93b97d7751e86c88e7f066397fde99ed23043f4255bb6f82705bc602c0f118 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1579428/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -130403000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000095017024019118/axsm-20231231.htm#2576352 Filing: 000095017024019118 The citation records this snapshot. The page link may show a newer release later.	−USD 108.23 million Exact value Exact value: -108226000 USD 2021-01-01 – 2021-12-31: -108226000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Axsome Therapeutics, Inc. · 2021-12-31 Axsome Therapeutics, Inc. (edgar:1579428) Operating Cash Flow: -108226000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T02:31:15Z Snapshot: ed93b97d7751e86c88e7f066397fde99ed23043f4255bb6f82705bc602c0f118 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1579428/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -108226000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000095017024019118/axsm-20231231.htm#1779303 Filing: 000095017024019118 The citation records this snapshot. The page link may show a newer release later.	USD 308,000 Exact value Exact value: 308000 USD 2021-01-01 – 2021-12-31: 308000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Axsome Therapeutics, Inc. · 2021-12-31 Axsome Therapeutics, Inc. (edgar:1579428) Capital Expenditure: 308000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T02:31:15Z Snapshot: ed93b97d7751e86c88e7f066397fde99ed23043f4255bb6f82705bc602c0f118 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1579428/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 308000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000095017024019118/axsm-20231231.htm#1786098 Filing: 000095017024019118 The citation records this snapshot. The page link may show a newer release later.	−USD 108.53 million Calculation and evidence -108226000 − 308000 USD Exact free cash flow: -108534000 USD 2021-01-01 – 2021-12-31: -108226000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 308000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Axsome Therapeutics, Inc. · 2021-12-31 Axsome Therapeutics, Inc. (edgar:1579428) Free cash flow: -108534000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T02:31:15Z Snapshot: ed93b97d7751e86c88e7f066397fde99ed23043f4255bb6f82705bc602c0f118 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1579428?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -108226000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000095017024019118/axsm-20231231.htm#1779303 Filing: 000095017024019118 Input fundies:CapitalExpenditure: 308000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000095017024019118/axsm-20231231.htm#1786098 Filing: 000095017024019118 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 187.13 million Exact value Exact value: -187134000 USD 2022-01-01 – 2022-12-31: -187134000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Axsome Therapeutics, Inc. · 2022-12-31 Axsome Therapeutics, Inc. (edgar:1579428) Net Income: -187134000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T02:31:15Z Snapshot: ed93b97d7751e86c88e7f066397fde99ed23043f4255bb6f82705bc602c0f118 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1579428/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -187134000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000095017025022457/axsm-20241231.htm#3643637 Filing: 000095017025022457 The citation records this snapshot. The page link may show a newer release later.	−USD 116.51 million Exact value Exact value: -116511000 USD 2022-01-01 – 2022-12-31: -116511000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Axsome Therapeutics, Inc. · 2022-12-31 Axsome Therapeutics, Inc. (edgar:1579428) Operating Cash Flow: -116511000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T02:31:15Z Snapshot: ed93b97d7751e86c88e7f066397fde99ed23043f4255bb6f82705bc602c0f118 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1579428/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -116511000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000095017025022457/axsm-20241231.htm#2132035 Filing: 000095017025022457 The citation records this snapshot. The page link may show a newer release later.	USD 702,000 Exact value Exact value: 702000 USD 2022-01-01 – 2022-12-31: 702000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Axsome Therapeutics, Inc. · 2022-12-31 Axsome Therapeutics, Inc. (edgar:1579428) Capital Expenditure: 702000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T02:31:15Z Snapshot: ed93b97d7751e86c88e7f066397fde99ed23043f4255bb6f82705bc602c0f118 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1579428/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 702000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000095017025022457/axsm-20241231.htm#2141090 Filing: 000095017025022457 The citation records this snapshot. The page link may show a newer release later.	−USD 117.21 million Calculation and evidence -116511000 − 702000 USD Exact free cash flow: -117213000 USD 2022-01-01 – 2022-12-31: -116511000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 702000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Axsome Therapeutics, Inc. · 2022-12-31 Axsome Therapeutics, Inc. (edgar:1579428) Free cash flow: -117213000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T02:31:15Z Snapshot: ed93b97d7751e86c88e7f066397fde99ed23043f4255bb6f82705bc602c0f118 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1579428?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -116511000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000095017025022457/axsm-20241231.htm#2132035 Filing: 000095017025022457 Input fundies:CapitalExpenditure: 702000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000095017025022457/axsm-20241231.htm#2141090 Filing: 000095017025022457 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 239.24 million Exact value Exact value: -239238000 USD 2023-01-01 – 2023-12-31: -239238000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Axsome Therapeutics, Inc. · 2023-12-31 Axsome Therapeutics, Inc. (edgar:1579428) Net Income: -239238000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T02:31:15Z Snapshot: ed93b97d7751e86c88e7f066397fde99ed23043f4255bb6f82705bc602c0f118 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1579428/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -239238000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000119312526064267/axsm-20251231.htm#3782370 Filing: 000119312526064267 The citation records this snapshot. The page link may show a newer release later.	−USD 145.08 million Exact value Exact value: -145080000 USD 2023-01-01 – 2023-12-31: -145080000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Axsome Therapeutics, Inc. · 2023-12-31 Axsome Therapeutics, Inc. (edgar:1579428) Operating Cash Flow: -145080000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T02:31:15Z Snapshot: ed93b97d7751e86c88e7f066397fde99ed23043f4255bb6f82705bc602c0f118 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1579428/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -145080000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000119312526064267/axsm-20251231.htm#2137033 Filing: 000119312526064267 The citation records this snapshot. The page link may show a newer release later.	USD 582,000 Exact value Exact value: 582000 USD 2023-01-01 – 2023-12-31: 582000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Axsome Therapeutics, Inc. · 2023-12-31 Axsome Therapeutics, Inc. (edgar:1579428) Capital Expenditure: 582000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T02:31:15Z Snapshot: ed93b97d7751e86c88e7f066397fde99ed23043f4255bb6f82705bc602c0f118 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1579428/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 582000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000119312526064267/axsm-20251231.htm#2146357 Filing: 000119312526064267 The citation records this snapshot. The page link may show a newer release later.	−USD 145.66 million Calculation and evidence -145080000 − 582000 USD Exact free cash flow: -145662000 USD 2023-01-01 – 2023-12-31: -145080000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 582000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Axsome Therapeutics, Inc. · 2023-12-31 Axsome Therapeutics, Inc. (edgar:1579428) Free cash flow: -145662000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T02:31:15Z Snapshot: ed93b97d7751e86c88e7f066397fde99ed23043f4255bb6f82705bc602c0f118 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1579428?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -145080000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000119312526064267/axsm-20251231.htm#2137033 Filing: 000119312526064267 Input fundies:CapitalExpenditure: 582000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000119312526064267/axsm-20251231.htm#2146357 Filing: 000119312526064267 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 287.22 million Exact value Exact value: -287216000 USD 2024-01-01 – 2024-12-31: -287216000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Axsome Therapeutics, Inc. · 2024-12-31 Axsome Therapeutics, Inc. (edgar:1579428) Net Income: -287216000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T02:31:15Z Snapshot: ed93b97d7751e86c88e7f066397fde99ed23043f4255bb6f82705bc602c0f118 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1579428/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -287216000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000119312526064267/axsm-20251231.htm#3780515 Filing: 000119312526064267 The citation records this snapshot. The page link may show a newer release later.	−USD 128.41 million Exact value Exact value: -128410000 USD 2024-01-01 – 2024-12-31: -128410000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Axsome Therapeutics, Inc. · 2024-12-31 Axsome Therapeutics, Inc. (edgar:1579428) Operating Cash Flow: -128410000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T02:31:15Z Snapshot: ed93b97d7751e86c88e7f066397fde99ed23043f4255bb6f82705bc602c0f118 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1579428/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -128410000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000119312526064267/axsm-20251231.htm#2135152 Filing: 000119312526064267 The citation records this snapshot. The page link may show a newer release later.	USD 270,000 Exact value Exact value: 270000 USD 2024-01-01 – 2024-12-31: 270000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Axsome Therapeutics, Inc. · 2024-12-31 Axsome Therapeutics, Inc. (edgar:1579428) Capital Expenditure: 270000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T02:31:15Z Snapshot: ed93b97d7751e86c88e7f066397fde99ed23043f4255bb6f82705bc602c0f118 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1579428/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 270000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000119312526064267/axsm-20251231.htm#2144593 Filing: 000119312526064267 The citation records this snapshot. The page link may show a newer release later.	−USD 128.68 million Calculation and evidence -128410000 − 270000 USD Exact free cash flow: -128680000 USD 2024-01-01 – 2024-12-31: -128410000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 270000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Axsome Therapeutics, Inc. · 2024-12-31 Axsome Therapeutics, Inc. (edgar:1579428) Free cash flow: -128680000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T02:31:15Z Snapshot: ed93b97d7751e86c88e7f066397fde99ed23043f4255bb6f82705bc602c0f118 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1579428?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -128410000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000119312526064267/axsm-20251231.htm#2135152 Filing: 000119312526064267 Input fundies:CapitalExpenditure: 270000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000119312526064267/axsm-20251231.htm#2144593 Filing: 000119312526064267 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 183.17 million Exact value Exact value: -183174000 USD 2025-01-01 – 2025-12-31: -183174000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Axsome Therapeutics, Inc. · 2025-12-31 Axsome Therapeutics, Inc. (edgar:1579428) Net Income: -183174000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T02:31:15Z Snapshot: ed93b97d7751e86c88e7f066397fde99ed23043f4255bb6f82705bc602c0f118 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1579428/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -183174000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000119312526064267/axsm-20251231.htm#3778660 Filing: 000119312526064267 The citation records this snapshot. The page link may show a newer release later.	−USD 93.41 million Exact value Exact value: -93405000 USD 2025-01-01 – 2025-12-31: -93405000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Axsome Therapeutics, Inc. · 2025-12-31 Axsome Therapeutics, Inc. (edgar:1579428) Operating Cash Flow: -93405000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T02:31:15Z Snapshot: ed93b97d7751e86c88e7f066397fde99ed23043f4255bb6f82705bc602c0f118 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1579428/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -93405000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000119312526064267/axsm-20251231.htm#2133272 Filing: 000119312526064267 The citation records this snapshot. The page link may show a newer release later.	USD 480,000 Exact value Exact value: 480000 USD 2025-01-01 – 2025-12-31: 480000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Axsome Therapeutics, Inc. · 2025-12-31 Axsome Therapeutics, Inc. (edgar:1579428) Capital Expenditure: 480000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T02:31:15Z Snapshot: ed93b97d7751e86c88e7f066397fde99ed23043f4255bb6f82705bc602c0f118 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1579428/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 480000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000119312526064267/axsm-20251231.htm#2142829 Filing: 000119312526064267 The citation records this snapshot. The page link may show a newer release later.	−USD 93.89 million Calculation and evidence -93405000 − 480000 USD Exact free cash flow: -93885000 USD 2025-01-01 – 2025-12-31: -93405000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 480000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Axsome Therapeutics, Inc. · 2025-12-31 Axsome Therapeutics, Inc. (edgar:1579428) Free cash flow: -93885000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T02:31:15Z Snapshot: ed93b97d7751e86c88e7f066397fde99ed23043f4255bb6f82705bc602c0f118 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1579428?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -93405000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000119312526064267/axsm-20251231.htm#2133272 Filing: 000119312526064267 Input fundies:CapitalExpenditure: 480000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1579428/000119312526064267/axsm-20251231.htm#2142829 Filing: 000119312526064267 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

90 filings · 2,607 latest values · 2,607 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001579428, 1579428, AXSM, edgar:1579428

Also known as AXSOME THERAPEUTICS, INC., Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation